Lineage Cell Therapeutics
LCTX
LCTX
105 hedge funds and large institutions have $73.1M invested in Lineage Cell Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 28 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less capital invested
Capital invested by funds: $103M → $73.1M (-$29.6M)
39% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 28
Holders
105
Holding in Top 10
3
Calls
$173K
Puts
$2K
Top Buyers
| 1 | +$310K | |
| 2 | +$291K | |
| 3 | +$173K | |
| 4 |
RA
Raffles Associates
New York
|
+$170K |
| 5 |
Citigroup
New York
|
+$148K |
Top Sellers
| 1 | -$581K | |
| 2 | -$235K | |
| 3 | -$172K | |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$151K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$78.8K |